Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Family Medicine | Internal Medicine | Critical Care | Emergency Medicine | Nursing | Pharmacy | Surgery | Journal

Back to Journal Articles

Biolimus Stents Noninferior to Sirolimus Stents

Last Updated: November 09, 2011.

 

Biolimus-eluting stents are noninferior to sirolimus eluting stents in coronary artery disease

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Biodegradable biolimus-eluting stents are noninferior to durable polymer sirolimus-eluting stents in coronary artery disease, according to a study published online Nov. 9 in The Lancet to coincide with its presentation at the Transcatheter Cardiovascular Therapeutics meeting, held from Nov. 7 to 11 in San Francisco.

WEDNESDAY, Nov. 9 (HealthDay News) -- Biodegradable biolimus-eluting stents (BES) are noninferior to durable polymer sirolimus-eluting stents (SES) in coronary artery disease (CAD), according to a study published online Nov. 9 in The Lancet to coincide with its presentation at the Transcatheter Cardiovascular Therapeutics meeting, held from Nov. 7 to 11 in San Francisco.

Giulio G. Stefanini, M.D., from the University of Bern in Switzerland, and colleagues compared the clinical outcomes of BES and SES during long-term (four years) follow-up of 1,707 patients with CAD. Cohorts of 857 and 850 patients were randomized to receive BES and SES, respectively, between Nov 2006 and May 2007. A composite of cardiac death, myocardial infarction, or clinically indicated target vessel revascularization was the primary end point.

The investigators found that, at the four-year follow-up point, BES was noninferior to SES with respect to the primary end point (rate ratio [RR], 0.81; P for noninferiority <0.0001, P for superiority = 0.050). Definite stent thrombosis (ST) had a RR of 0.62, largely due to the BES group having a significantly lower risk very-late definite ST risk between years one and four compared to the SES group (RR, 0.20). During the first year, the RR of definite ST was not significant (0.99). There was a positive test for the interaction between RR of definite ST and time; an interaction with time was recorded for events linked to ST, but not other events. The RRs for the primary end point events associated with ST were 0.86 and 0.17 during the first and subsequent years, respectively (Pinteraction = 0.049).

"Compared with durable polymer SES, biodegradable polymer BES are noninferior," the authors write.

Several of the study authors disclosed financial ties with the pharmaceutical and medical device industries, including Biosensors Europe, which funded the study and manufactures drug eluting and bare metal stents.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information

Copyright © 2011 HealthDay. All rights reserved.


Previous: HPV-16/18 Efficacious Against CIN3+, Adenocarcinoma in Situ Next: North American Spine Society, Nov. 2-5, 2011

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.